JTO Clinical and Research Reports最新文献

{"title":"Corrigendum to ‘Humanized Mouse Models for Immuno-Oncology Research: A Review and Implications in Lung Cancer Research’ [JTO Clinical and Research Reports Volume 6 Issue 3 (2025) 100781]","authors":"Cheol-Kyu Park MD, PhD , Maryam Khalil BSc , Nhu-An Pham PhD , Stephanie Wong BSc , Dalam Ly PhD , Adrian Sacher MD, FRCPC , Ming-Sound Tsao MD, FRCPC","doi":"10.1016/j.jtocrr.2025.100824","DOIUrl":"10.1016/j.jtocrr.2025.100824","url":null,"abstract":"","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 5","pages":"Article 100824"},"PeriodicalIF":3.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discordant Response to Nivolumab Plus Ipilimumab and Identification of BRAF V600E Mutation in Biphasic Malignant Pleural Mesothelioma: Case Report","authors":"Olivia Wilkins DO ,&nbsp;Adedamola Omogbehin MD ,&nbsp;Peter J. Bergquist MD ,&nbsp;Chul Kim MD, MPH ,&nbsp;Stephen V. Liu MD ,&nbsp;Joshua E. Reuss MD","doi":"10.1016/j.jtocrr.2025.100820","DOIUrl":"10.1016/j.jtocrr.2025.100820","url":null,"abstract":"<div><div>Therapeutic advancement for malignant pleural mesothelioma (MPM) has been limited. Combination immunotherapy with nivolumab plus ipilimumab is a frontline treatment option for advanced MPM that is typically deployed for patients with sarcomatoid or biphasic MPM. Here, we present a case of biphasic MPM that exhibited a unique response pattern to first-line treatment with nivolumab plus ipilimumab, with brisk response in pleural and mediastinal sites of disease, but rapid progression in osseous/soft tissue sites of disease complicated by pathologic spinal cord compression. Pathologic findings from bony metastasis at progression found pure epithelioid histology without any evidence of sarcomatoid differentiation. Next-generation sequencing of this specimen revealed a <em>BRAF</em> V600E mutation, and the patient was subsequently treated with dabrafenib plus trametinib, achieving ongoing clinical and imaging response in all sites of the disease, including bones. This case supports the use of next-generation sequencing profiling in MPM, particularly in circumstances in which novel discordant response patterns are observed.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 5","pages":"Article 100820"},"PeriodicalIF":3.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143697854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase 2 Trial of Combination Radiotherapy and Pembrolizumab Plus Chemotherapy in Patients With Previously Untreated Metastatic NSCLC: NJLCG 1902","authors":"Yoko Tsukita MD, PhD ,&nbsp;Rei Umezawa MD, PhD ,&nbsp;Taku Nakagawa MD, PhD ,&nbsp;Akira Anbai MD, PhD ,&nbsp;Tomonori Makiguchi MD, PhD ,&nbsp;Hisashi Tanaka MD, PhD ,&nbsp;Yosuke Horii MD, PhD ,&nbsp;Aya Suzuki MD ,&nbsp;Ryo Morita MD, PhD ,&nbsp;Hitomi Nogawa MD ,&nbsp;Hiroshi Yokouchi MD, PhD ,&nbsp;Nozomu Kimura MD, PhD ,&nbsp;Keiichi Jingu MD, PhD ,&nbsp;Akira Inoue MD, PhD ,&nbsp;Hisatoshi Sugiura MD, PhD ,&nbsp;Eisaku Miyauchi MD, PhD","doi":"10.1016/j.jtocrr.2025.100817","DOIUrl":"10.1016/j.jtocrr.2025.100817","url":null,"abstract":"<div><h3>Introduction</h3><div>Treatment strategies that enhance the efficacy of immunotherapy are desired. Radiotherapy can enhance immunity, but the utility of adding radiotherapy to immunotherapy plus platinum-doubled chemotherapy in patients with metastatic NSCLC has not been explored.</div></div><div><h3>Methods</h3><div>This multicenter, single-arm phase 2 trial evaluated the efficacy and safety of combining radiotherapy with pembrolizumab plus chemotherapy in patients with previously untreated metastatic NSCLC. Patients begin receiving pembrolizumab plus platinum-doublet chemotherapy within 1 week of starting radiotherapy (30 Gy in 10 fractions). The primary end point was the 12-month progression-free survival (PFS) rate. The secondary end points included PFS, overall survival, and toxicity profiles.</div></div><div><h3>Results</h3><div>Forty patients were enrolled. In total, 37 and 38 patients were analyzed for efficacy and safety, respectively. The 12-month PFS rate was 44.3% (90% confidence interval [CI]: 30.3–57.3), which met the primary end point. The median PFS was 8.4 months (95% CI: 5.7–22.2), and the median overall survival was 30.1 months (95% CI: 22.3–not reached). Grade 3 or 4 adverse events occurred in 25 patients (65.8%), and one treatment-related death was reported. Pneumonitis was reported in 10 patients (26.3%), including two cases of grade 3 pneumonitis and one case of grade 5.</div></div><div><h3>Conclusions</h3><div>Adding radiotherapy to pembrolizumab plus platinum-doublet chemotherapy led to promising efficacy in patients with previously untreated metastatic NSCLC. Although caution should be exercised with regard to pneumonitis, adverse events were tolerable. Further research is needed to confirm the efficacy and safety of this strategy.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 5","pages":"Article 100817"},"PeriodicalIF":3.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acknowledgment of Reviewers","authors":"","doi":"10.1016/S2666-3643(25)00026-8","DOIUrl":"10.1016/S2666-3643(25)00026-8","url":null,"abstract":"","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 3","pages":"Article 100810"},"PeriodicalIF":3.0,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143488857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Model-Based Cost-Utility Analysis of Combined Low-Dose Computed Tomography Screening for Lung Cancer, Chronic Obstructive Pulmonary Disease, and Cardiovascular Disease","authors":"Carina M. Behr PhD ,&nbsp;Maarten J. IJzerman PhD ,&nbsp;Michelle M.A. Kip PhD ,&nbsp;Harry J.M. Groen MD, PhD ,&nbsp;Marjolein A. Heuvelmans MD, PhD ,&nbsp;Maarten van den Berge MD, PhD ,&nbsp;Pim van der Harst MD, PhD ,&nbsp;Marleen Vonder PhD ,&nbsp;Rozemarijn Vliegenthart MD, PhD ,&nbsp;Hendrik Koffijberg PhD","doi":"10.1016/j.jtocrr.2025.100813","DOIUrl":"10.1016/j.jtocrr.2025.100813","url":null,"abstract":"<div><h3>Introduction</h3><div>The conditional cost-effectiveness of low-dose computed tomography for lung cancer (LC) screening has been reported. Extending LC screening to chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD), together with Big-3, could increase health benefits at marginal costs. This study aimed to estimate the cost-utility of Big-3 screening compared with no screening and LC screening in The Netherlands.</div></div><div><h3>Methods</h3><div>A microsimulation model was built to reflect the care pathway, using individual-level data from the National Lung Screening Trial individual-level data, and aggregated data from the literature. The model includes a simulation of the detection of the Big-3 diseases through screening and standard of care. The model also simulated tumor growth and the effects of smoking cessation and treatment. Hypothetical (former) smokers (aged 55–74 y) were simulated according to the National Lung Screening Trial criteria. Individuals with screening-detected diseases receiving (preventative) treatment experience a reduced risk of events and increased survival. A Dutch health system perspective and lifetime horizon were adopted.</div></div><div><h3>Results</h3><div>Simultaneous LC and CVD screening was the most cost-effective, with incremental costs and effects of €1937 and 0.22 quality-adjusted life-years (QALYs) versus no screening, and €595 and 0.08 QALYs versus LC screening, respectively. This yielded incremental cost-utility ratios of €8561 per QALY and €7154 per QALY versus no screening and LC screening, respectively. LC plus COPD screening was dominated by LC + CVD screening, which yielded lower health benefits and higher costs.</div></div><div><h3>Conclusions</h3><div>Simultaneous screening for LC + CVD in a high-risk population offers health benefits at low costs compared with no screening or LC screening alone. Adding COPD screening cannot yet be justified owing to the limited clinical evidence.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 5","pages":"Article 100813"},"PeriodicalIF":3.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143746252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Yttrium-90 Radioembolization for Hepatic Metastases Secondary to Thymic Malignancies: A Case Report","authors":"Gavin Yuan BA,&nbsp;Elena N. Petre MD,&nbsp;Etay Ziv MD, PhD,&nbsp;Brett Marinelli MD,&nbsp;Ken Zhao MD,&nbsp;Vlasios Sotirchos MD,&nbsp;Erica S. Alexander MD","doi":"10.1016/j.jtocrr.2025.100812","DOIUrl":"10.1016/j.jtocrr.2025.100812","url":null,"abstract":"<div><div>The current guidelines for the treatment of extrathoracic metastases secondary to thymic neoplasms recommend chemotherapy. Thymic carcinomas are radiosensitive, and radiation therapy is recommended for intrathoracic masses and isolated metastases that are not amenable to resection. Liver-directed therapy, particularly yttrium-90 radioembolization, has been used for the treatment of oligometastatic diseases in the liver from various primaries. Here, we report three cases of radioembolization for the treatment of thymic carcinoma that metastasized to the liver.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 5","pages":"Article 100812"},"PeriodicalIF":3.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143768436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation–Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)","authors":"Chee Khoon Lee PhD ,&nbsp;Bin-Chi Liao MD ,&nbsp;Shalini Subramaniam MMed (Clin Epi) ,&nbsp;Chao-Hua Chiu MD ,&nbsp;Antony J. Mersiades MMed (Clin Epi) ,&nbsp;Chao-Chi Ho MD, PhD ,&nbsp;Chris Brown MBiostats ,&nbsp;Chun-Liang Lai MD, PhD ,&nbsp;Brett G.M. Hughes M.B.B.S. (Hons) ,&nbsp;Tsung-Ying Yang MD, PhD ,&nbsp;Ken O’Byrne MD ,&nbsp;Yung-Hung Luo MD, PhD ,&nbsp;Sonia Yip PhD ,&nbsp;Ching-Liang Ho MD ,&nbsp;Victoria Bray PhD ,&nbsp;Wu-Chou Su MD, PhD ,&nbsp;Melissa Moore PhD ,&nbsp;Wei-Lien Feng MS ,&nbsp;Ya-Ying Bai MS ,&nbsp;Kate Ford MHSc ,&nbsp;James Chih-Hsin Yang MD, PhD","doi":"10.1016/j.jtocrr.2024.100771","DOIUrl":"10.1016/j.jtocrr.2024.100771","url":null,"abstract":"<div><h3>Introduction</h3><div><em>EGFR</em>-mutant NSCLC is associated with low mutation burden and low levels of PD-L1 expression. We conducted a phase 2 trial to determine the efficacy of durvalumab, tremelimumab, and platinum-pemetrexed in <em>EGFR-</em>mutant NSCLC after progression with EGFR tyrosine kinase inhibitors (TKIs).</div></div><div><h3>Methods</h3><div>Participants were treated with induction durvalumab, tremelimumab, and platinum-pemetrexed, followed by durvalumab-pemetrexed maintenance. Participants were divided into two cohorts: (1) <em>EGFR</em> exon 20 T790M negative (T790M−, progressing on either first-line osimertinib, or on a single line of first/second generation TKI), and (2) T790M positive (T790M+, progressing on greater than or equal to 1 lines of TKI, including osimertinib). The primary endpoint was the confirmed objective response rate (ORR) assessed by the investigators. Progression-free survival and safety were secondary outcomes.</div></div><div><h3>Results</h3><div>One hundred participants from Australia and Taiwan were enrolled. Median follow-up was 26 months with 88% and 96% experiencing progression events for T790M− and T790M+, respectively. The ORR for T790M− was 31% (95% confidence interval: 20–45), including two complete responses. The ORR for T790M+ was 21% (95% confidence interval: 12–34). Median durations of response were 9.5 months and 6.3 months for T790M− and T790M+, respectively; median progression-free survival rates were 6.5 months and 4.9 months, respectively. For T790M−, ORR was 27% for 50% or higher PD-L1 (n = 22) and 0% for less than 50% PD-L1 (n = 10), respectively. For T790M+, ORR was 17% for 50% or higher PD-L1 (n = 24). The safety profile was consistent with previous reports.</div></div><div><h3>Conclusions</h3><div>Durvalumab, tremelimumab, and platinum-pemetrexed had modest anti-tumor activity in <em>EGFR-</em>mutant NSCLC after progression on TKI. The T790M− cohort had higher ORR and a longer duration of response. Immune adverse events were not increased with tremelimumab. The clinical registration number of this trial is NCT03994393.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 2","pages":"Article 100771"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143059562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Prophylactic Use of PEG-rhG-CSF on First-Line Immunochemotherapy in Advanced NSCLC: A Cohort Study","authors":"Li Sun MD,&nbsp;Yuan Tian MD,&nbsp;Shuling Zhang MD, PhD,&nbsp;Letian Huang MD,&nbsp;Jietao Ma MD, PhD,&nbsp;Chengbo Han MD, PhD","doi":"10.1016/j.jtocrr.2024.100780","DOIUrl":"10.1016/j.jtocrr.2024.100780","url":null,"abstract":"<div><h3>Introduction</h3><div>This study aimed to assess the impact of prophylactic use of PEG-rhG-CSF on first-line immunochemotherapy in advanced NSCLC.</div></div><div><h3>Methods</h3><div>A cohort of patients with advanced NSCLC who received first-line immunochemotherapy at Shengjing Hospital of China Medical University between January 2019 and July 2024 was selected for this study. Patients were divided into the following two groups: a treatment group that received prophylactic PEG-rhG-CSF (≥1 cycle) 48 hours after immunochemotherapy and a control group that did not receive PEG-rhG-CSF. The primary end points were progression-free survival (PFS), overall survival (OS), overall response rate, and safety. A propensity score-matched analysis was performed to reduce potential confounders.</div></div><div><h3>Results</h3><div>A total of 220 patients were enrolled, with 87 in the treatment group and 133 in the control group. Median PFS was 10.5 months in both the treatment and control groups (<em>p</em> = 0.86), and median OS was 33.9 months in the treatment group versus not reached in the control group (<em>p</em> = 0.71). The overall response rate was 64.4% in the treatment group and 58.6% in the control group (<em>p</em> = 0.40). After propensity score-matched analysis (each group included 78 patients), median PFS was 12.6 months in the treatment group versus 10.5 months in the control group (<em>p</em> = 0.99), and median OS remained 30.3 months in the treatment group versus not reached in the control group (<em>p</em> = 0.85). The treatment group had a reduced incidence of chemotherapy interruptions, any grade of leukopenia, any grade of neutropenia, and grades 3 to 5 neutropenia, without an increase in immune-related adverse events.</div></div><div><h3>Conclusions</h3><div>The prophylactic use of PEG-rhG-CSF in patients with advanced NSCLC undergoing first-line immunochemotherapy did not compromise efficacy and safety. It reduced chemotherapy interruptions and neutropenia, without increasing immune-related adverse events, thus supporting safe and uninterrupted treatment.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 2","pages":"Article 100780"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143059496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Response Letter to Kosaka et al. Regarding Manuscript Titled: “Radiotherapy Improves Survival in Non–Small Cell Lung Cancer Following Oligoprogression on Immunotherapy: A Cohort Study”","authors":"Lauren Julia Brown M.B.B.S., MClinTRes, FRACP,&nbsp;Julie Ahn M.B.B.S.,&nbsp;Bo Gao BmedSci, M.B.B.S., FRACP, PhD,&nbsp;Harriet Gee M.B.B.S., DPhil, FRANZCR,&nbsp;Adnan Nagrial M.B.B.S., FRACP, PhD,&nbsp;Inês Pires da Silva MD, FRACP, PhD,&nbsp;Eric Hau BSc (Med), M.B.B.S., Grad Cert (Biostat), FRANZCR, PHD","doi":"10.1016/j.jtocrr.2024.100767","DOIUrl":"10.1016/j.jtocrr.2024.100767","url":null,"abstract":"","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 2","pages":"Article 100767"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773209/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143059560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors","authors":"Nathaniel J. Myall MD ,&nbsp;Jennifer G. Whisenant PhD ,&nbsp;Joel W. Neal MD, PhD ,&nbsp;Wade T. Iams MD ,&nbsp;Karen L. Reckamp MD ,&nbsp;Sally York MD, PhD ,&nbsp;Lynne D. Berry PhD ,&nbsp;Yu Shyr PhD ,&nbsp;Leora Horn MD ,&nbsp;Heather A. Wakelee MD ,&nbsp;Sukhmani K. Padda MD","doi":"10.1016/j.jtocrr.2024.100757","DOIUrl":"10.1016/j.jtocrr.2024.100757","url":null,"abstract":"<div><h3>Introduction</h3><div>Although tyrosine kinase inhibitors (TKIs) are effective against NSCLC harboring sensitizing <em>EGFR</em> gene mutations, acquired resistance is inevitable. Preclinical studies suggest that combining EGFR TKI and monoclonal antibody therapies may have activity in <em>EGFR-</em>mutated NSCLC that has progressed on TKI therapy alone. Therefore, we prospectively evaluated afatinib plus necitumumab in patients with <em>EGFR-</em>mutated NSCLC.</div></div><div><h3>Methods</h3><div>This was a phase 1, dose-escalation, dose-expansion trial assessing the safety and efficacy of afatinib plus necitumumab. Patients had advanced or metastatic <em>EGFR-</em>mutated NSCLC with progression after (1) first-generation TKI if T790M negative, (2) subsequent line third-generation TKI if T790M positive, or (3) third-generation TKI in the first-line setting. Dose-escalation followed a 3+3 design. The primary end point of dose-expansion was objective response rate.</div></div><div><h3>Results</h3><div>A total of 22 patients with <em>EGFR</em>-mutated NSCLC were enrolled. The maximum tolerated dose was afatinib 40 mg oral daily plus necitumumab 600 mg intravenous on days 1 and 15 every 28 days. There were no grade 4 to 5 adverse events observed, and seven patients (32%) experienced grade 3 treatment-related adverse events (three rash; one each oral mucositis, diarrhea, headache, ventricular arrhythmia, and tachycardia). In the entire cohort, there were no responses observed, the median progression-free survival was 1.8 months, and the disease control rate was 36% but varied between the subgroups.</div></div><div><h3>Conclusions</h3><div>Afatinib plus necitumumab was safe but had limited activity in patients with <em>EGFR-</em>mutated NSCLC. Biomarker studies may identify patient subgroups that are more likely to benefit.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 2","pages":"Article 100757"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11759541/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}